{"id":"NCT02505542","sponsor":"UCB BIOSCIENCES GmbH","briefTitle":"Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo","officialTitle":"A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07","primaryCompletion":"2019-02","completion":"2019-04","firstPosted":"2015-07-22","resultsPosted":"2020-04-21","lastUpdate":"2020-12-17"},"enrollment":736,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Axial Spondyloarthrithis","Ankylosing Spondylitis"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab Pegol","otherNames":["Cimzia","CDP870"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Open-label Certolizumab Pegol","type":"OTHER"},{"label":"Double-blind Certolizumab Pegol 200 mg Q2W","type":"EXPERIMENTAL"},{"label":"Double-blind Certolizumab Pegol 200 mg Q4W","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Placebo to CZP 200 mg Q2W escape","type":"OTHER"},{"label":"CZP 200 mg Q4W to CZP 200 mg Q2W escape","type":"OTHER"},{"label":"CZP 200 mg Q2W to CZP 200 mg Q2W escape","type":"OTHER"}],"summary":"Patients receive study drug for one year (Part A). If, after the initial run-in phase, a sustained remission is reached they will be randomly split into one of three dose groups for another year (Part B). The maintenance of the sustained remission will be analyzed.","primaryOutcome":{"measure":"Percentage of Participants in Part B Who Did Not Experienced a Flare","timeFrame":"From Week 48 to Week 96","effectByArm":[{"arm":"Placebo Double-Blind (RS)","deltaMin":20.2,"sd":null},{"arm":"Certolizumab Pegol 200 mg Q2W Double-Blind (RS)","deltaMin":83.7,"sd":null},{"arm":"Certolizumab Pegol 200 mg Q4W Double-Blind (RS)","deltaMin":79,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":12},"locations":{"siteCount":108,"countries":["United States","Belgium","Bulgaria","Czechia","France","Germany","Hungary","Netherlands","Poland","Romania","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["32381562","40256636","39231546","32529495"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":736},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Pharyngitis","Bronchitis","Axial spondyloarthritis"]}}